This fruit was found to enhance anti-tumor effects, overcome PD-1 resistance through gut flora
Time of Update: 2022-03-06
Results showed increased tumor growth in mice treated with CC and anti-CD8+ monoclonal antibody compared to CC/IsoCD8+ (control), suggesting that the microbiome-mediated effects of CC are CD8+ T cell-dependent .
"The Lancet-Oncology": What about PD-(L)1 resistance in NSCLC patients?
Time of Update: 2022-02-20
Previous studies have confirmed that the combination of PD(L)-1 inhibitors and CTLA-4 inhibitors shows synergy and has been used for first-line treatment of metastatic non-small cell lung cancer (NSCLC) .
PD-1 resistance is expected to be solved! TIM-3 Target approved clinical, Hengrui, BMS, Roche latest progress...
Time of Update: 2020-07-10
Introduction: PD-1/L1 first echelon, competition for new directions foreword: Recently, Novartis in the study of TIM-3 monoclonal antibody MBG453 obtained a clinical trial license, and this antibody
Save PD-1 resistance! More effective regulation of adenosine pathway by CD39 antibody
Time of Update: 2019-11-14
Tumor immunotherapy is considered to be one of the most successful methods in the field of cancer treatment in recent years However, PD-1 / PD-L1 antibody can not escape the cycle of drug resistance C
with pembrolizumab in patients with advanced melanoma resistant to PD-1 immunotherapy
Time of Update: 2022-05-18
This is a single-arm study (NCT04570332) of intratumoral BO-112 and intravenous pembrolizumab in patients with melanoma (skin, condyloma, or mucosa) receiving anti-PD1 therapy and confirmed progressive disease (PD) .
Phase 1/2 clinical trial of nitric oxide synthase inhibitor L-NMMA and taxane in the treatment of chemotherapy-resistant triple-negative breast cancer
Time of Update: 2021-12-27
Successful combinationA phase 1/2 clinical trial tested the effects of inducible nitric oxide synthase inhibitor (L-NMMA) combined with taxane in the treatment of refractory locally advanced breast cancer (LABC) and metastatic triple-negative breast cancer (TNBC) Curative effect .
Cancer Cell: Determinants of anti-PD-1 response and drug resistance in advanced renal cell carcinoma
Time of Update: 2021-12-03
Importantly, almost all of these genes are mainly expressed in non-responders before treatment, indicating that HERV and LTR elements that are highly specific to ccRCC are overexpressed before treatment in non-responders, and are related to anti-tumor immune responses and anti-PD- 1 Reaction defect is related .
On October 1, 2021, Song Hai and Shen Li's research group collaborated to discover a new mechanism
Time of Update: 2021-10-09
In the study of the mechanism of this phenomenon, the researchers found that the expression of YAP in small cell lung cancer can significantly activate the NOTCH signaling pathway .
Those things about emery wear-resistant floor (Part 1)-Crafts
Time of Update: 2021-09-11
After curing agent construction, it can effectively improve the surface hardness (expressed by indentation diameter) and wear resistance (expressed by grinding pit length), the surface is denser, the integrity is better, and it can effectively prevent sanding and dusting; 3) Waterproof, oil-proof and anti-corrosion Ordinary emery floors have pores invisible to the naked eye on the surface.
Nat Med: What is the effect of tumor infiltrating lymphocyte treatment for patients with anti-PD-1 drug-resistant metastatic lung cancer?
Time of Update: 2021-08-26
It can be seen that autologous TIL cell therapy is generally safe and clinically active, and may be used as a new treatment for patients with metastatic lung cancer .
Autologous TIL cell therapy is generally safe and clinically active, and may be used as a new treatment for patients with metastatic lung cancer .
Initiation of triple immunization program clinical trial for PD-1/L1 monoclonal antibody treatment of drug-resistant prenabulin
Time of Update: 2021-06-22
It is reported that this trial was initiated by researchers to evaluate the safety and tolerability of pranabulin, PD-1/PD-L1 antibody and radiotherapy triple therapy in patients with 7 types of metastatic or locally advanced cancer Sex .
Initiation of triple immunization program for PD-1/L1 monoclonal antibody treatment of drug-resistant prenabulin...
Time of Update: 2021-06-12
It is reported that this trial was initiated by researchers to evaluate the safety and tolerability of pranabulin, PD-1/PD-L1 antibody and radiotherapy triple therapy in patients with 7 types of metastatic or locally advanced cancer Sex.
prognosis of patients with advanced melanoma resistant to PD-1
Time of Update: 2021-05-20
Two reported grade 3-5 adverse events similar proportion of patients with immuneTo sum up, in patients with melanoma who are resistant to anti-PD-(L)1 therapy, the efficacy of ipilimumab combined with anti-PD-1 therapy is significantly higher than that of ipilimumab monotherapy, which not only improves the objective remission rate, but also Both progression-free survival and overall survival were significantly prolonged .
See the trick: What should I do if PD-1/PD-L1 immunotherapy drugs are resistant?
Time of Update: 2021-04-27
· Internal reasons for drug resistance: tumor cells are very cunning and will bypass immunotherapy through many mechanisms, such as affecting neoantigen expression, antigen presentation, and affecting immune co-suppressive signals.
Intriguing Phase 1: Anti-multidrug-resistant pulmonary tuberculosis treatment plan curative effect detection prediction
Time of Update: 2021-04-14
They believe that the current monitoring of the efficacy of multi-drug-resistant tuberculosis is mostly based on the comprehensive judgment of the patient’s clinical manifestations, sputum and imaging test results, but it is not an ideal indicator, especially for patients with diabetic tuberculosis, it is difficult to determine the course of treatment and Timing of withdrawal.